R2 in the Treatment of Follicular Lymphoma

Shanghai Jiao Tong University

Status and phase: Unknown; Phase 2

Conditions: Follicular Lymphoma

Treatments: Drug: Revlimid

Study type: Interventional

Funder types: Other

Identifiers

NCT03715309

RJ-R2

Details and patient eligibility

About

Lenalidomide Based Immunotherapy in the Treatment of FL

Full description

Lenalidomide Based Immunotherapy efficacy related molecular biomarker in follicular lymphoma

Enrollment: 115 estimated patients

Sex: All

Ages: 16 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients diagnose as de novo or relapse refractory FL grade 1-3A .

No history of stem cell transplantation.

Written informed consent.

Exclusion criteria

Chemotherapy or large field radiotherapy within 3 weeks prior to entering the study.

Clinically significant active infection.

Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule.

Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures.

Subject has ≥grade 2 peripheral neuropathy or grade 1 with pain within 14 days before enrollment.

Patients who are pregnant or breast-feeding.

HIV infection.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

115 participants in 1 patient group

Revlimd

Experimental group

Treatment:

Drug: Revlimid